BIOA on Nasdaq
BioAge Labs, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with International Stem Cell CORP, Praxis Precision Medicines, Inc. or PROTHENA CORP PUBLIC LTD CO, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1031.5%Operating margin3
-896.1%Net margin3
-29.6%Return on equity3
0.00×Debt to equity3
-$82.3MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$74.0M
Out of $9.0M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $9.0M | $0 |
| Research and development | $74.0M | $59.0M |
| General and administrative | $27.8M | $19.2M |
| Total operating expenses | $101.8M | $78.2M |
| Loss from operations | -$92.8M | -$78.2M |
| Interest expense | -$697.0K | -$2.4M |
| Interest and other income (expense), net | $13.1M | $9.6M |
| Gain (loss) from changes in fair value of warrants | -$214.0K | $73.0K |
| Loss on extinguishment of debt | $0 | -$250.0K |
| Total other income (expense), net | $12.2M | $7.1M |
| Net loss | -$80.6M | -$71.1M |
| Net loss per share attributable to common stockholders, Basic | -$2.24 | -$6.63 |
| Net loss per share attributable to common stockholders, Diluted | -$2.24 | -$6.63 |
| Weighted-average common shares outstanding, basic | 35.9M shares | 10.7M shares |
| Weighted-average common shares outstanding, dilutive | 35.9M shares | 10.7M shares |
| Unrealized holding gains on available-for-sale investments | $122.0K | $0 |
| Foreign currency translation adjustment | -$89.0K | $81.0K |
| Total other comprehensive income | $33.0K | $81.0K |
| Total comprehensive loss | -$80.6M | -$71.0M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $188.9M | $354.3M | |
| Marketable securities, current | $92.2M | $0 | |
| Accounts receivable | $769.0K | $0 | |
| Prepaid expenses and other current assets | $4.9M | $2.8M | |
| Total current assets | $286.8M | $357.1M | |
| Investments | $100.0K | $100.0K | |
| Marketable securities | $4.0M | $0 | |
| Property and equipment, net | $963.0K | $591.0K | |
| Operating lease right-of-use assets | $2.8M | $200.0K | |
| Other assets | $216.0K | $240.0K | |
| Total assets | $294.9M | $358.2M | |
| Accounts payable | $2.7M | $2.0M | |
| Accrued expenses and other current liabilities | $8.5M | $11.8M | |
| Current portion of term loan | $2.6M | $6.0M | |
| Operating lease liabilities, current | $582.0K | $202.0K | |
| Deferred revenue, current | $5.8M | $7.8M | |
| Total current liabilities | $20.1M | $27.8M | |
| Deferred revenue | $0 | $4.7M | |
| Term loan | $0 | $2.5M | |
| Warrant liability | $370.0K | $156.0K | |
| Operating lease liabilities | $2.3M | $0 | |
| Total liabilities | $22.8M | $35.1M | |
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31,2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.00001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 37,386,908 and 35,850,037 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in-capital | $605.2M | $575.7M | |
| Accumulated other comprehensive income | $278.0K | $245.0K | |
| Accumulated deficit | -$333.4M | -$252.8M | |
| Total stockholders' equity | $272.1M | $323.1M | |
| Total liabilities and stockholders' equity | $294.9M | $358.2M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 37.4M shares | 35.9M shares | |
| Common stock, shares outstanding | 37.4M shares | 35.9M shares | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, share authorized | 10.0M shares | 10.0M shares | 10.0M shares |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$80.6M | -$71.1M |
| Stock-based compensation expense | $11.7M | $7.0M |
| Depreciation expense | $213.0K | $167.0K |
| Loss on extinguishment of debt | $0 | $250.0K |
| Non-cash interest expense | $163.0K | $1.0M |
| Non-cash lease expense | $125.0K | $3.0K |
| (Gain) loss from changes in fair value of warrants | $214.0K | -$73.0K |
| Loss on disposal of property and equipment | $23.0K | $55.0K |
| Accretion of net investment discounts | -$1.6M | |
| Accounts receivable | -$769.0K | $0 |
| Prepaid expenses and other current assets | -$1.7M | -$2.4M |
| Other Assets | $24.0K | -$240.0K |
| Accounts payable | $788.0K | $6.0K |
| Accrued expenses and other current liabilities | -$3.4M | $4.6M |
| Deferred grant income | $0 | -$3.3M |
| Deferred revenue | -$6.7M | $12.5M |
| Net cash used in operating activities | -$81.6M | -$51.5M |
| Purchase of property and equipment | -$719.0K | -$366.0K |
| Purchases of marketable securities | -$154.7M | $0 |
| Maturities of marketable securities | $60.2M | $0 |
| Net cash used in investing activities | -$95.2M | -$366.0K |
| Proceeds from Series D issuance | $0 | $170.0M |
| Issuance costs paid on Series D issuance | $0 | -$542.0K |
| Proceeds from initial public offering, net of underwriting discounts and commissions | $0 | $211.8M |
| Issuance costs paid on initial public offering and private placement | $0 | -$4.5M |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | $0 | $9.9M |
| Proceeds from issuance of common stock through at-the-market facility, net of commissions | $17.2M | $0 |
| Issuance costs paid on at-the market offering | -$64.0K | $0 |
| Deferred offering costs paid | -$336.0K | $0 |
| Term loan principal payments | -$6.0M | -$6.0M |
| Proceeds from issuance of common shares upon stock option exercises | $714.0K | $634.0K |
| Net cash provided by financing activities | $11.5M | $381.2M |
| Effect of changes in exchange rate on cash and cash equivalents | -$87.0K | $81.0K |
| Net increase (decrease) in cash and cash equivalents | -$165.5M | $329.4M |
| Unpaid purchases of property and equipment | $13.0K | $124.0K |
| Conversion of convertible promissory notes into Series D-1 redeemable convertible preferred stock | $0 | $40.7M |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | $0 | $342.8M |
| Cash paid for interest | $611.0K | $1.4M |
| Unpaid equity issuance costs included in accounts payable and accrued expenses | $123.0K | $0 |
| Right-of-use assets obtained in exchange for lease obligation | $3.1M | $282.0K |
Recent filings
- Oct 2, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 1, 20264
- Jun 30, 2026144
- Jun 29, 2026144
- Jun 12, 20268-K
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- May 15, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6